Especially, FABP4 (aP2), a suggested biomarker for non-alcoholic fatty liver disease (NAFLD) and HCC [16], was up-regulated in PPAR signaling pathway by a positive feedback regulation and continually acted on PPAR signaling pathway in both sexes, which may play important roles in steatosis and carcinogenesis. The gene discussed is FABP4; the disease is metabolic dysfunction-associated steatotic liver disease.